Rev­o­lu­tion Med­i­ci­nes' KRAS drug shows po­ten­tial in ear­ly cut of lung can­cer da­ta

CHICA­GO — An ex­per­i­men­tal KRAS G12D drug from Rev­o­lu­tion Med­i­cines made waves last year as a po­ten­tial treat­ment for pan­cre­at­ic can­cer. On Sun­day, new re­sults …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER